Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Potential for AI as first reader in lung cancer screening
2
Zitationen
10
Autoren
2025
Jahr
Abstract
AI reading showed comparable sensitivity but lower specificity than human reading. High NPV of AI may support its use as a first reader in LCS.
Ähnliche Arbeiten
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.791 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.470 Zit.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.860 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.979 Zit.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2015 · 9.414 Zit.